NeoGenomics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
NeoGenomics, Inc. (NEO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.32 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-17
- NeoGenomics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $1.32M, a 143.83% increase from fiscal 2024.
- NeoGenomics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $543.00K, a 61.61% increase from fiscal 2023.
- NeoGenomics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $336.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $1.32M 10-K · filed 2026-02-17 |
| 2024-12-31 | $543.00K 10-K · filed 2026-02-17 |
| 2023-12-31 | $336.00K 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |